How sequential studies inform drug development: Evaluating the effect of Food intake on optimal bioavailability of ziprasidone

Journal of Psychiatric Practice

Volumn 16, Issue 2, 2010, Pages 103-114

  Lincoln, Jana ^a   Stewart, Mark E ^b   Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Antipsychotics; Bioavailability; Clinical trial design; Drug development; Food intake; Ziprasidone

Indexed keywords

ZIPRASIDONE;

AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; CALORIC INTAKE; CLINICAL TRIAL; DIET RESTRICTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG TOLERABILITY; FOOD INTAKE; HUMAN; LIPID DIET; LOW CALORY DIET; MAXIMUM PLASMA CONCENTRATION; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; STEADY STATE; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOMEDICAL RESEARCH; BIPOLAR DISORDER; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG MONITORING; DRUGS, INVESTIGATIONAL; ENERGY INTAKE; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PIPERAZINES; POSTPRANDIAL PERIOD; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952182765     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000369971.64908.dc     Document Type: Article

References (18)

1. Geodon (ziprasidone) prescribing information. New York, NY: Pfizer, Inc.; 2007.
2. Center for Drug Evaluation and Research (CDER). Guidance for industry: Food-effect bioavailability and fed bioequivalence studies. Rockville, MD: U. S. Department of Health and Human Services, Food and Drug Administration, CDER; 2002 (available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ UCM126833pdf. accessed November 5, 2009).
3. Center for Drug Evaluation and Research (CDER). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products: General considerations. Rockville, MD: U. S. Department of Health and Human Services, Food and Drug Administration, CDER; March 2003 (available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070124pdf, accessed November 5, 2009).
4. Center for Drug Evaluation and Research (CDER). Guidance for industry: Statistical approaches to establishing bioequivalence. Rockville, MD: U. S. Department of Health and Human Services, Food and Drug Administration, CDER; January 2001 (available at www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInform ation/Guidances/ucm070244pdf, accessed November 5, 2009).
5. Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 1998;18:9-15.
6. Miceli JJ, Glue P, Alderman J, et al. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull 2007;40:58-68.
7. Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: A randomized, open-label, crossover trial. J Clin Psychiatry 2009;70:58-62.
8. Preskorn SH. Patients who do not respond to the "usual" dose: Why Terry fell off the dose-response curve. J Psychiatr Pract 2009;15:460-6.
9. Preskorn SH. Clinical relevance of relative receptor binding affinity: Quetiapine and ziprasidone as examples. J Psychiatr Pract 2007;13:393-8.
10. Weiden PJ, Preskorn SH, Fahnestock PA, et al. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: A roadmap. J Clin Psychiatry 2007; 68 (suppl 7) : 1-46.
11. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone, Am J Psychiatry 2004;161:818-25.
12. Janicak PG, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy, fourth edition, Philadelphia: Lippincott Williams & Wilkins, 2006
13. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
14. Nyberg S, Farde L, Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. Psychiatry Res 1996;67:163-71.
15. Goff DC, Posever T, Herz L. An exploratory haloperidolcontrolled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
16. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clinical Psychiatry 2007; 68 (suppl 1) : 20-7.
17. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease, Am Heart J 2005;150:1115-21.
18. Citrome L. Using oral ziprasidone effectively: The food effect and dose response. Adv Ther 2009;26:739-48.